Patent · US Active

MCL1 inhibitors

US11667652B2 · kind B2 · utility

2Cited by
3References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 10, 2020
Grant dateJun 6, 2023
Priority date—
Expiry dateDec 30, 2040

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.